Pharmacoepidemiological analysis of the drugs used for secondary prevention of brain infarction on dispensary stage

Bibliography:
1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics — 2013 update: a report from the American Heart Association. Circulation 2013; 27 (1): e6-e245; 2. Gusev El, Skvortsova VI, Stakhovskaya LV. Epidemiology of stroke in Russia. Neurology and psychiatry. Stroke 2003; 8: 4-9; 3. Gusev El, Shimrigk G, Haas N. Results of three years follow-up of patients with ischemic stroke (based on the data bank for stroke). Journal of Neurology 2002; 5:10-14; 4. Boqueria LA, Stupakov IN, Gudkova RG. Successes and problems of the Russian heart surgery. Health 2012; 3: 24-33; 5. Vilensky BS. Strokeprevention, diagnosisandtreatment. St. Petersburg: Foliant, 2002; p. 336-337; 6. Vorlou ChP, Dennis MS, van Gein J, et al. Stroke: A Practical Guide for the management of patients. St. Petersburg: Politekhnika, 1998; 629 p.; 7. Damulin IV, Parfenov VA, Skoromets AA, et. al. Poor circulation in the brain and spinal cord. In: Diseasesofthenervoussystem: a guide for physicians. Moscow: Medicine, 2005. Vol. 1; p. 231-302; 8. Parfenov VA. Antiplatelet agentsin thetreatment and secondaryprevention of ischemicstroke. Nevrology and psychiatry 2007; 10: 812-817; 9. Suslina ZA, Piradov MA. Stroke: diagnosis, treatment and prevention. Moscow: MED presslnform, 2008; 288 p.; 10. Suslina ZA, Tanashyan MM, lonov VG. Ischemic stroke, blood, vascularwall, antithrombotictherapy. Moscow: MedicalBook, 2005; 248 p.; 11. Feigin V, Vibers D, Brown R. Stroke: A clinical guide. Moscow: Binom; St. Petersburg: Dialect, 2005; 608 p.; 12. Skvortsov VI, Chazova IE, Stakhovskaya LV. Secondary stroke prevention. Moscow: PAGRI, 2002; 120 p.; 13. Guide lines for managemen tof ischaemic stroke and transient ischaemic attack 2008. Cerebrovascular Diseases 2008; 25 (5): 457-507; 14. Fonyakin AV, Geraskina LA, Shandalin VA. Prevention of cardiovascularcomplications after stroke: standards, realityand prospects. Neurology, neuropsychiatry, psychosomatics 2010; 1: 24-29; 15. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378 (9798): 1231-1243; 16. Shandalin VA, Fonyakin AV, GeraskinaLA. Secondary preventionof ischemic stroke: from recommendations-toreal clinical practice. Neurology, neuropsychiatry Psychosomatics2012; 2: 35-41; 17. Saposnik G, Goodman SG, Leiter LA. et. al. Applying the evidence: do patients withst roke, coronaryartery disease, or bothachieve similar treatment goals? Stroke 2009; 40:1417-1424; 18. World Health Organisation: adherence to longterm therapies, evidence for action. Geneva: WHO, 2003; 19. Simpson DT, Eurich SR, Majumdar RS, et al. A meta-analysis of the association between adherence to drug therapy and mortality. British Medical Journal 2006; 333: 15; 20. Osterberg L, Blaschke T. Adherence to medication. The New England Journal of Medicine 2005; 353: 487-497; 21. Parfenov VA. Secondary preventionof ischemic stroke. Russian Journal of Medicine2005; 12:819-823; 22. Parfenov VA. Prevention of ischemic strokere-optimization of antiplatelet therapy. Russian Journal of Medicine 2009; 20: 361-365; 23. Gusev El, Boiko AN, Sidorenko TV, et al. Commitment and other primary therapy in patients with post-stroke depression. Journal of Neurology 2011; 16 (4): 54-59; 24. Vasilevska OV, Safina DD, Silantieva IV Causes of inefficiency secondary prevention of ischemic insulta. Kazansky Medical Journal 2012; 93 (5): 744-748; 25. Boytsov SA, Martsevich SJ, et al. Lubertsy mortality study of patients after stroke or transient ischemic attack (LIS-2). Design and evaluation of drug therapy. Rational Pharmacotherapy in Cardiology 2013; 9 (2): 114-122; 26. Petrov VI. Applied pharmacoepidemiology. Moscow: GEOTAR-Media, 2008; 384 p.; 27. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovascular Diseases 2008; 25 (5): 457-507; 28. Gusev El, Konovalov AN, Skvortsova VI, et al. Neurology: national leadership. Moscow: GEOTAR-Media, 2009; 1112 p.; 29. Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment. Cochrane Database of Systematic Reviews 2001; 2. Art. No.: CD001011; 30. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association / American Stroke Association. Stroke 2013; 44: 870-947; 31. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378 (9798): 1231-1243; 32. Dohoung Kim, Seung-Hoon, Lee et al. Secondary prevention by stroke subtype: a nationwide follow-up study in 46108 patients after acute ischaemic stroke. European Heart Journal 2013; doi: 10.1093/eurheartj/eht185; 33. Ostrovsky VO. Evaluationclinical practice: patients with acutecerebral ischemia. Herbal Gazette 2012, 6 (46): 31-38; 34. Alfimova GY, Maslov NN. Register stroke in the Smolensk region. In: Materials 5th Interregional Scientific and Practical Conference "Actual issues of Neurology". Bulletin of Siberian Medicine 2008; 5: 19-23; 35. Chichanovskaya LV. Epidemiology of cerebral stroke in the Tver region. In: Proceedings of the international conference "Topical issues of public health policy". Tver, 2002; p. 25-28; 36. Kachemaeva OB, Borisova NA. Epidemiological characteristics of stroke in Ufa, according to the register. Neurological herald them Bekhterev 2007; 39 (1): 45-48; 37. Diagnosis and treatment of atrial fibrillation: recommendations RKO VNOA and ASSKH, 2012. Moscow: 2012; 38. Camm AJ, Kirchhof Р, Lip GYH, et al. Guidelines for themanagementofatrialfibrillation: the Task Forceforthe Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal 2010; 31 (19): 2369-2429; 39. Suslin ZA, Varakin YY. Epidemiological aspects of studying stroke. Timeto sum up. Anal Clinical and Experimental Neurology 2007; 1 (2): 22-28; 40. Chuchalin AG, Belousov YB, Yasnetsov VV Federal guidelines on the use ofdrugs (formulary system). Moscow: Echoes 2009; X:944 p.; 41. De Deyn PP. et al. Treatment of Acute Ischemic Stroke Wth Piracetam. Stroke 1997; 28: 2347-2352; 42. Ratmanova A. Ischemic stroke and neuroprotection: the search continues. Medicine Review 2008; 3 (03): 38-44; 43. Recommendations for Imaging of Acute Ischemic Stroke: A Scientific Statement From the American Heart Association. Stroke 2009; 40: 3646-3678; 44. Adams H, Adams R, Del Zoppo G, Goldstein LB. Stroke Council of the American Heart Association; American Stroke Association. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association. Stroke 2005; 36 (4): 916-923; 45. European Stroke Initiative (EUSI) Recommendations for Stroke Management: Update 2003. Cerebrovascular Diseases 2003; 16:311-337; 46. Parfenov VA. Risk factors forischemic stroke andsec-ondaryprevention. Neurology, neuropsychiatry. Psychosomatics 2010; 3: 40-45; 47. Zateyschikov DA, Isayev MJ. Questions organization anticoagulation. Clinical Practice 2012; 3: 51-62.